AURKA and rhabdoid tumor: Previous trials have explored the use of aurora A kinase inhibition in malignant rhabdoid tumors, with an attempt to augment radiation sensitivity in cell lines that overexpress AAK, which occurs in cells with mutations in SMARCB1.